Palvella Therapeutics names Kent Taylor sales chief Apr 7, 2026 12:26PM
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales Apr 7, 2026 07:30AM
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 15, 2025 05:34PM
Syndax (SNDX) and Incyte (INCY) Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo Sep 18, 2024 05:17PM
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease Sep 18, 2024 05:15PM
View Older Stories

Aug 14, 2024 05:34PM Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Jan 23, 2024 08:00AM Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
Jan 8, 2024 08:31AM Incyte (INCY) Highlights Growth Opportunities and Provides Business Updates
Jan 8, 2024 08:30AM Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 10, 2023 05:00PM Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
Jul 24, 2023 07:02AM Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Jul 24, 2023 07:00AM Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Jun 12, 2023 04:01PM Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
Apr 16, 2023 03:01PM MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Dec 5, 2022 07:06AM Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Dec 5, 2022 07:00AM Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Nov 7, 2022 08:17AM Incyte (INCY) And Mirati (MRTX) Enters Collaboration and Supply Agreement to Evaluate INCB99280
Nov 7, 2022 08:15AM Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
Jun 13, 2022 09:50PM FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Jun 13, 2022 04:01PM Pfizer (PFE), MorphoSys (MOR) and Incyte (INCY) Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Jun 13, 2022 04:01PM Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
May 20, 2022 08:13AM CHMP Recommends Approval of Lilly (LLY) and Incyte's (INCY) OLUMIANT (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata
May 20, 2022 08:11AM CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
May 11, 2022 06:45AM Eli Lilly & Co. (LLY) and Incyte (INCY) Announce FDA Approval of OLUMIANT for Treatment of Certain Hospitalized Patients with COVID-19
May 11, 2022 06:45AM FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
May 9, 2022 04:29PM Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
Feb 28, 2022 04:36PM Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
Jan 25, 2022 04:32PM Merus N.V. (MRUS) Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
Jan 25, 2022 04:30PM Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
Jan 25, 2022 04:30PM Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
Dec 13, 2021 05:27AM NASDAQ (NDAQ) Announces Changes to the Nasdaq-100 Index
Dec 10, 2021 08:00PM Annual Changes to the Nasdaq-100 Index®
Sep 27, 2021 06:13AM Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Pact for Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Sep 27, 2021 06:00AM Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Sep 17, 2020 01:44PM Eli Lilly (LLY) Said Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19
Sep 17, 2020 01:41PM Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
Feb 27, 2020 09:00AM Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)
Feb 12, 2020 05:54AM Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib
Dec 5, 2019 08:00AM Incyte to Present at Upcoming Investor Conference
Nov 27, 2019 07:30AM Incyte (INCY) Announces Acceptance, Priority Review of NDA for Pemigatinib as Treatment for Patients with Cholangiocarcinoma
Nov 27, 2019 07:30AM Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
Nov 25, 2019 08:00AM Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting
Nov 14, 2019 08:00AM Incyte to Present at Upcoming Investor Conference
Oct 29, 2019 07:00AM Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Oct 22, 2019 08:00AM Incyte to Present at Upcoming Investor Conference
Oct 16, 2019 07:01AM Incyte (INCY) Reports REACH2 Pivotal Trial of Ruxolitinib (Jakafi) Meets Primary Endpoint
Oct 16, 2019 07:00AM Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Oct 14, 2019 06:14AM Incyte (INCY) Reports Positive 52-Wk Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
Oct 12, 2019 02:32AM Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
Oct 10, 2019 08:00AM Incyte to Report Third Quarter Financial Results
Sep 27, 2019 08:01AM Incyte (INCY) Reports Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients
Sep 27, 2019 08:00AM Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
Sep 25, 2019 07:31AM Incyte (INCY) Reports First Patient Treatment in Ph. 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
Sep 25, 2019 07:30AM Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
Sep 23, 2019 07:30AM Incyte to Host Investor Conference Call from ESMO 2019
View Older Stories